178 related articles for article (PubMed ID: 11213438)
1. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release.
Ruckmani K; Muneera MS; Vijaya R
Boll Chim Farm; 2000; 139(5):205-8. PubMed ID: 11213438
[TBL] [Abstract][Full Text] [Related]
2. Microencapsulation of ketorolac tromethamine by means of a coacervation-phase separation technique induced by the addition of non-solvent.
Genç L; Demirel M; Güler E; Hegazy N
J Microencapsul; 1998; 15(1):45-53. PubMed ID: 9463806
[TBL] [Abstract][Full Text] [Related]
3. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of khaya gum as a directly compressible matrix system for controlled release.
Odeku OA; Fell JT
J Pharm Pharmacol; 2004 Nov; 56(11):1365-70. PubMed ID: 15525442
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery.
Moustafine RI; Margulis EB; Sibgatullina LF; Kemenova VA; Van den Mooter G
Eur J Pharm Biopharm; 2008 Sep; 70(1):215-25. PubMed ID: 18691856
[TBL] [Abstract][Full Text] [Related]
6. Citric acid as a solid-state plasticizer for Eudragit RS PO.
Schilling SU; Shah NH; Malick AW; Infeld MH; McGinity JW
J Pharm Pharmacol; 2007 Nov; 59(11):1493-500. PubMed ID: 17976259
[TBL] [Abstract][Full Text] [Related]
7. Development and in vitro evaluations of gelatin A microspheres of ketorolac tromethamine for intranasal administration.
Sankar C; Mishra B
Acta Pharm; 2003 Jun; 53(2):101-10. PubMed ID: 14764244
[TBL] [Abstract][Full Text] [Related]
8. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets.
Akhgari A; Sadeghi F; Garekani HA
Int J Pharm; 2006 Aug; 320(1-2):137-42. PubMed ID: 16782290
[TBL] [Abstract][Full Text] [Related]
9. Dissolution behaviour of sustained release formulations of indomethacin with Eudragit RS.
Khanfar MS; Salem MS; Najib NM; Pillai GK
Acta Pharm Hung; 1997 Nov; 67(6):235-9. PubMed ID: 9423295
[TBL] [Abstract][Full Text] [Related]
10. The influence of Eudragit type on the dissolution rate of acetylsalicylic acid from matrix tablets.
Jovanović M; Jovicić G; Djurić Z; Agbaba D; Karljiković-Rajić K; Nikolić L; Radovanović J
Acta Pharm Hung; 1997 Nov; 67(6):229-34. PubMed ID: 9423294
[TBL] [Abstract][Full Text] [Related]
11. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA
Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673
[TBL] [Abstract][Full Text] [Related]
12. Ketorolac tromethamine formulations: an overview.
Sinha VR; Kumar RV; Singh G
Expert Opin Drug Deliv; 2009 Sep; 6(9):961-75. PubMed ID: 19663721
[TBL] [Abstract][Full Text] [Related]
13. Accelerated stability of Ibuprofen-Eudragit RSPM sustained release tablets, IR and DSC solid stability testing.
Abdel Rahman AA; Aboutaleb AE; Stamm A; Samy EM; Abdel-Rahman SI
J Pharm Belg; 1993; 48(6):463-70. PubMed ID: 8133428
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of ofloxacin sustained release pellets.
Cui Y; Zhang Y; Tang X
Int J Pharm; 2008 Aug; 360(1-2):47-52. PubMed ID: 18538518
[TBL] [Abstract][Full Text] [Related]
15. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation.
Sultana Y; Aqil M; Ali A
Acta Pharm; 2005 Sep; 55(3):305-14. PubMed ID: 16375841
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of tetrandrine alginate calcium sustained release gel pellets].
Ma Y; Li WZ; Chen DW
Zhong Yao Cai; 2008 Jan; 31(1):131-4. PubMed ID: 18589765
[TBL] [Abstract][Full Text] [Related]
17. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
Sauer D; Zheng W; Coots LB; McGinity JW
Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
[TBL] [Abstract][Full Text] [Related]
18. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
19. Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets.
Abbaspour MR; Sadeghi F; Afrasiabi Garekani H
Eur J Pharm Biopharm; 2008 Mar; 68(3):747-59. PubMed ID: 17977701
[TBL] [Abstract][Full Text] [Related]
20. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers.
Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW
Drug Dev Ind Pharm; 2006 Jun; 32(5):569-83. PubMed ID: 16720412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
